Publication Type:

Journal Article

Source:

Current drug delivery, Volume 10, Number 3, p.326-335 (2013)

URL:

http://www.scopus.com/inward/record.url?eid=2-s2.0-84885337598&partnerID=40&md5=b3f141496dbc2b6bf4e107d4ea6eb398

Keywords:

analogs and derivatives, Antimetabolites, Antineoplastic, antineoplastic antimetabolite, article, cell adhesion, Cell Line, Cell Survival, chemistry, chitosan, Deoxycytidine, drug delivery system, Drug Delivery Systems, drug derivative, drug effect, Drug effects, female, Fibrin, gemcitabine, human, Humans, nanocomposite, Nanocomposites, Ovarian Neoplasms, ovary tumor, Pectin, Pectins, porosity, tissue scaffold, Tissue Scaffolds, Tumor, tumor cell line

Abstract:

Ovarian cancer is the ninth most common cancer amongst women and ranked as fifth in terms of the cause of cancer related mortality accounting for more deaths than any other cancer of the female reproductive system. Gemcitabine is the most common chemotherapeutic agent used in the treatment of ovarian cancer despite of its disadvantage of having a very lesser half life. In this study, we have envisaged the use of a highly porous, biomimetic and implantable pectin scaffold embedded with gemcitabine loaded fibrin nanoconstructs to improve the half life of the drug, thereby providing localized therapy for ovarian cancer. The controlled and sustained release of the chemokine from the scaffold system was extensively analyzed in vitro different pH environments. The composite scaffolds were found to be highly biocompatible when tested with mammalian cell lines. The excellent cytotoxicity and apoptosis responses induced in ovarian cancer, PA- 1 cell lines proved that the nanocomposite Pectin scaffolds loaded with specific chemokine can be used as implantable "therapeutic wafers" for distracting metastatic cancer cells and thus improve the survival rate of ovarian cancer afflicted individuals.

Notes:

cited By 2

Cite this Research Publication

, “Potential use of drug loaded nano composite pectin scaffolds for the treatment of ovarian cancer.”, Current drug delivery, vol. 10, pp. 326-335, 2013.